Semaglutide in the United States
WEGOVY is an FDA-approved semaglutide product under NDA 215256. Ozempic and Rybelsus are separate semaglutide products with separate applications, presentations, and labeled uses. The ingredient name alone does not establish which product, indication, dose form, prescription record, pharmacy route, or seller applies, and it does not transfer FDA approval to compounded or unapproved semaglutide.
- Evidence lane
- FDA-approved medicine
- Global identity
- Product-specific approved medicine records in multiple jurisdictions